Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25892444 | 1.00 | MAOB (0.45) | MAOBESR1ESR2MAPTMAPK1 | |
| SCHEMBL25892495 | 1.00 | MAOB (0.45) | MAOBESR1ESR2MAPTMAPK1 | |
| SCHEMBL19771459 | 0.94 | ESR1 (0.50) | MAOBESR1ESR2MAPTMAPK1 | |
| SCHEMBL24103715 | 0.90 | MAPT (0.53) | MAOBESR1ESR2MAPTMAPK1 | |
| SCHEMBL245538 | 0.90 | MAPT (0.53) | MAOBESR1ESR2MAPTMAPK1 | |
| SCHEMBL30362815 | 0.90 | MAPT (0.53) | MAOBESR1ESR2MAPTMAPK1 | |
| SCHEMBL25893256 | 0.90 | MAPT (0.53) | MAOBESR1ESR2MAPTMAPK1 | |
| SCHEMBL10042954 | 0.89 | ESR1 (0.55) | MAOBESR1ESR2MAPTMAPK1 | |
| SCHEMBL15965358 | 0.89 | ESR1 (0.38) | MAOBESR1ESR2MAPTMAPK1 | |
| SCHEMBL15965357 | 0.89 | ESR1 (0.38) | MAOBESR1ESR2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-05-19 | — | — | US | disclosed |
| US-9198895-B2 | Chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150238458-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-08-27 | — | — | US | disclosed |
| US-8957109-B2 | Chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140161908-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8461361-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8163795-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120004296-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238458-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | MAOB 2314/4885ESR1 1699/4885ESR2 1586/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | MAOB 2663/4885ESR1 3784/4885ESR2 2187/4885 |
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | MAOB 2314/4885ESR1 1699/4885ESR2 1586/4885 |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | MAOB 2314/4885ESR1 1699/4885ESR2 1586/4885 |
| US-20140161908-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | MAOB 1587/4885ESR1 1565/4885ESR2 1800/4885 |
| US-20120004296-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | MAOB 2314/4885ESR1 1699/4885ESR2 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.